Literature DB >> 2757437

Transsternal radical thymectomy for myasthenia gravis: a 15-year review.

P D Hatton1, J T Diehl, B D Daly, H F Rheinlander, H Johnson, J B Schrader, M Bloom, R J Cleveland.   

Abstract

Thymectomy is an accepted therapeutic modality for patients with myasthenia gravis. The selection of patients for operation and the surgical approach are controversial. We reviewed 52 patients (aged 18 months to 82 years; mean age, 34 years) treated with transsternal radical thymectomy between 1972 and 1987. Patients were symptomatically staged according to the modified Osserman classification. There was one hospital death and postoperative follow-up was obtained on 51 patients. Improvement after thymectomy was observed in 3 of 11 patients (27%) in Osserman stage I, 16 of 25 patients (64%) in Osserman stage IIA, and 13 of 15 patients (86%) in combined Osserman stages IIB, III, and IV. Preoperative Osserman stage, patient sex, and thymic histology correlated with postoperative clinical response. Transsternal radical thymectomy is effective therapy for myasthenia gravis. Sustained improvement is obtained in patients with moderate and advanced disease. The majority of patients with ocular disease do not benefit from operation.

Entities:  

Mesh:

Year:  1989        PMID: 2757437     DOI: 10.1016/0003-4975(89)90015-5

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  12 in total

1.  Surgical treatment of myasthenia gravis in two major Middle East teaching hospitals: factors influencing outcome.

Authors:  S A Hassantash; D G Ashbaugh; E D Verrier; R V Maier
Journal:  Thorax       Date:  1996-02       Impact factor: 9.139

Review 2.  Long-term outcome and quality of life after thymectomy for myasthenia gravis.

Authors:  C Busch; A Machens; U Pichlmeier; T Emskötter; J R Izbicki
Journal:  Ann Surg       Date:  1996-08       Impact factor: 12.969

3.  Thymectomy and Risk of Generalization in Patients with Ocular Myasthenia Gravis: A Multicenter Retrospective Cohort Study.

Authors:  Huanhuan Li; Zhe Ruan; Feng Gao; Hongyu Zhou; Rongjing Guo; Chao Sun; Quan Xu; Qiang Lu; Yongan Zhou; Zhengwei Zhao; Liping Yu; Songdi Wu; Tao Lei; Ting Gao; Yonglan Tang; Chunhong Li; Feiyan Huo; Ying Zhu; Jie Sun; Baoli Tang; Min Zhang; Yanwu Gao; Xiaodan Lu; Zhuyi Li; Ting Chang
Journal:  Neurotherapeutics       Date:  2021-10-08       Impact factor: 6.088

4.  Hemorrhagic complication during robotic surgery in patient with thymomatous myasthenia gravis.

Authors:  Dario Amore; Roberto Scaramuzzi; Davide Di Natale; Carlo Curcio
Journal:  J Vis Surg       Date:  2018-02-27

5.  Ocular myasthenia gravis: controversies and updates.

Authors:  Sui H Wong; Saif Huda; Angela Vincent; Gordon T Plant
Journal:  Curr Neurol Neurosci Rep       Date:  2014-01       Impact factor: 5.081

6.  Thymectomy through lateralized partial sternotomy.

Authors:  Prashant N Mohite; Sandip Singh Rana; Prasanth Sadasivan; Swapnil Deshpande
Journal:  J Cardiovasc Dis Res       Date:  2011-07

7.  Factors predicting surgical outcome of thymectomy in myasthenia gravis: A 16-year experience.

Authors:  Nilkamal Kumar; A K Verma; A Mishra; G Agrawal; A Agrawal; U K Misra; S K Mishra
Journal:  Ann Indian Acad Neurol       Date:  2011-10       Impact factor: 1.383

Review 8.  Ocular myasthenia gravis: a review.

Authors:  Akshay Gopinathan Nair; Preeti Patil-Chhablani; Devendra V Venkatramani; Rashmin Anilkumar Gandhi
Journal:  Indian J Ophthalmol       Date:  2014-10       Impact factor: 1.848

9.  Thoracoscopic Thymectomy for Myasthenia Gravis: Seven Years of Clinical Experience.

Authors:  Abolghasem Daneshvar Kakhaki; Seyed Amir Mousavian; Kambiz Sheikhy
Journal:  Tanaffos       Date:  2016

10.  Clinical outcome of thymectomy in myasthenia gravis patients: A report from Iran.

Authors:  Benyamin Seyfari; Farzad Fatehi; Abolfazl Shojaiefard; Mehdi Jafari; Ali Ghorbani-Abdehgah; Shirzad Nasiri; Aidin Yaghoobi-Notash; Behnam Molavi; Amir Hossein Latif; Reza Eslamian; Ali Mir; Ahmadreza Soroush
Journal:  Iran J Neurol       Date:  2018-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.